Open an account

Radiopharm Theranostics

RADX · ASX

$1.01+$0.06 (+6.32%)TodayMarket closed ·
Prev close $0.95

About RADX

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria and currently employs 14 full-time employees. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.

Employees
14
Headquarters
Melbourne, Victoria
Listed
Nov 25, 2021
Sector
Health Care
Industry
Biotechnology
Website
radiopharmtheranostics.com

RADX key statistics

Market cap
18.84M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
52.44K
Volume
32.47K
Open price
$0.9669
High today
$1.07
Low today
$0.9991
52 Week high
$16.25
52 Week low
$0.90

Radiopharm Theranostics (RADX) at a glance

Radiopharm Theranostics (RADX) last traded at $1.01, with a market cap of 18.84M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9991 and $1.07. The current price is 1.1% above the day's low and 6.0% below its high.

Volume so far is 32.47K shares, below the average of 52.44K shares a day.

Over the past year Radiopharm Theranostics has ranged from $0.90 to $16.25, and now sits 1% of the way up that range.

The average analyst price target is $14.98, 1382.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $14.98
Low
$14.83
Now
$1.01
High
$15.42

RADX news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    US Stocks Mixed; American Express Shares Fall Following Q2 Results

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Vandana Singh

    Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results

  • 12 Health Care Stocks Moving In Monday's After-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.